WarfarinPharmacogeneticsVitamin K Epoxide ReductasesAnticoagulantsMixed Function OxygenasesAryl Hydrocarbon HydroxylasesIndividualized MedicineInternational CooperationCytochrome P-450 CYP2D6Polymorphism, GeneticGenotypeProthrombin TimeHemorrhageBiomarkers, PharmacologicalThromboembolismAtrial FibrillationMicrobial ConsortiaPolymorphism, Single Nucleotidebeta-AlanineDrug-Related Side Effects and Adverse ReactionsVitamin KDrug Dosage CalculationsInternational AgenciesPharmaceutical PreparationsDrug InteractionsGenetic VariationGenetic TestingDrug TherapyRodenticidesTreatment OutcomeCytochrome P-450 Enzyme SystemMetabolic Detoxication, DrugPharmacy ResidenciesAcenocoumarolStrokeDose-Response Relationship, DrugDihydrouracil Dehydrogenase (NADP)Drug MonitoringInternationalityRisk FactorsUnited StatesAspirinMethyltransferasesClinical Trials as TopicPlatelet Aggregation InhibitorsVitamin K 1Cytochrome P-450 CYP3AGenome-Wide Association StudyInternational Normalized RatioPhenotypeDrug DesignCohort StudiesPharmacokineticsRisk AssessmentAllelesGene Frequency4-HydroxycoumarinsBlood CoagulationGenetic Predisposition to DiseaseIntracranial HemorrhagesAzathioprineBenzimidazolesGenome, Human6-MercaptopurineNeoplasmsRetrospective StudiesAdministration, OralGlucuronosyltransferaseSleep Arousal DisordersAntipsychotic AgentsProspective StudiesOrganic Anion TransportersCodeineStevens-Johnson SyndromeBiotransformationEmbolismDrug ResistanceHaplotypesRandomized Controlled Trials as TopicVenous Thrombosis